Zilucoplan (Zilbrysq) for myasthenia gravis.
Författaruppgift saknas
Med Lett Drugs Ther · journal article · DOI 10.58347/tml.2024.1700c PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för zilucoplan. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
19 träffarPhase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria.
Kulasekararaj AG, Lehtinen AE, Forsyth C, Gandhi S, Griffin M, Körper S, Mikala G, Muus P, Overgaard U, Patriquin CJ, Pullon H, Shen YM, Spearing R, Szer J, De la Borderie G, Duda PW, Farzaneh-Far R, Ragunathan S, Sayegh CE, Vadysirisack DD, Schrezenmeier H.
Haematologica · letter; clinical trial, phase ii; research support, non-u.s. gov't · DOI 10.3324/haematol.2022.281780Improvement of fatigue in generalised myasthenia gravis with zilucoplan.
Weiss MD, Freimer M, Leite MI, Maniaol A, Utsugisawa K, Bloemers J, Boroojerdi B, Howard E, Savic N, Howard JF.
J Neurol · clinical trial, phase iii; research-article; randomized controlled trial; journal article · DOI 10.1007/s00415-024-12209-3The Efficacy and Safety of Different Targeted Drugs for the Treatment of Generalized Myasthenia Gravis: A Systematic Review and Bayesian Network Meta-analysis.
Ma Y, Nie X, Zhu G, Qi W, Hao L, Guo X.
CNS Drugs · systematic review; network meta-analysis; journal article · DOI 10.1007/s40263-024-01062-7Myasthenia Gravis Treatment: From Old Drugs to Innovative Therapies with a Glimpse into the Future.
Crisafulli S, Boccanegra B, Carollo M, Bottani E, Mantuano P, Trifirò G, De Luca A.
CNS Drugs · review; journal article · DOI 10.1007/s40263-023-01059-8Zilucoplan: First Approval.
Shirley M.
Drugs · review-article; review; journal article · DOI 10.1007/s40265-023-01977-3What Is in the Neuromuscular Junction Literature?
Lacomis D.
J Clin Neuromuscul Dis · journal article · DOI 10.1097/cnd.0000000000000456Zilucoplan
Författaruppgift saknas
Tidskrift saknas · reviewCorrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.
Tang GQ, Tang Y, Dhamnaskar K, Hoarty MD, Vyasamneni R, Vadysirisack DD, Ma Z, Zhu N, Wang JG, Bu C, Cong B, Palmer E, Duda PW, Sayegh C, Ricardo A.
Front Immunol · published erratum; correction · DOI 10.3389/fimmu.2023.1282155Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.
Tang GQ, Tang Y, Dhamnaskar K, Hoarty MD, Vyasamneni R, Vadysirisack DD, Ma Z, Zhu N, Wang JG, Bu C, Cong B, Palmer E, Duda PW, Sayegh C, Ricardo A.
Front Immunol · research support, non-u.s. gov't; research-article; journal article · DOI 10.3389/fimmu.2023.1213920Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis.
Saccà F, Pane C, Espinosa PE, Sormani MP, Signori A.
Eur J Neurol · systematic review; network meta-analysis; journal article · DOI 10.1111/ene.15872Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
Howard JF, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y, Juntas-Morales R, Kaminski HJ, Maniaol A, Mantegazza R, Masuda M, Sivakumar K, Śmiłowski M, Utsugisawa K, Vu T, Weiss MD, Zajda M, Boroojerdi B, Brock M, de la Borderie G, Duda PW, Lowcock R, Vanderkelen M, Leite MI, RAISE Study Team.
Lancet Neurol · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/s1474-4422(23)00080-7Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial.
Mammen AL, Amato AA, Dimachkie MM, Chinoy H, Hussain Y, Lilleker JB, Pinal-Fernandez I, Allenbach Y, Boroojerdi B, Vanderkelen M, Delicha EM, Koendgen H, Farzaneh-Far R, Duda PW, Sayegh C, Benveniste O.
Lancet Rheumatol · research-article; journal article · DOI 10.1016/s2665-9913(23)00003-6Prevention of Anti-HMGCR Immune-Mediated Necrotising Myopathy by C5 Complement Inhibition in a Humanised Mouse Model.
Julien S, Vadysirisack D, Sayegh C, Ragunathan S, Tang Y, Briand E, Carrette M, Jean L, Zoubairi R, Gondé H, Benveniste O, Allenbach Y, Drouot L, Boyer O.
Biomedicines · research-article; journal article · DOI 10.3390/biomedicines10082036Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial.
De Leeuw E, Van Damme KFA, Declercq J, Bosteels C, Maes B, Tavernier SJ, Detalle L, Smart T, Glatt S, Debeuf N, Deckers J, Lameire S, Vandecasteele SJ, De Neve N, Demedts IK, Govaerts E, Knoop C, Vanhove K, Moutschen M, Terryn W, Depuydt P, Van Braeckel E, Haerynck F, Hendrickx TCJ, Parrein V, Lalla M, Brittain C, Lambrecht BN.
Respir Res · research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1186/s12931-022-02126-2Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis.
Howard JF, Vissing J, Gilhus NE, Leite MI, Utsugisawa K, Duda PW, Farzaneh-Far R, Murai H, Wiendl H.
Expert Opin Investig Drugs · review; journal article · DOI 10.1080/13543784.2021.1897567Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan.
Gorman DM, Lee J, Payne CD, Woodruff TM, Clark RJ.
Amino Acids · brief-report; journal article · DOI 10.1007/s00726-020-02921-5Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): A structured summary of a study protocol for a randomised controlled trial.
Declercq J, Bosteels C, Van Damme K, De Leeuw E, Maes B, Vandecauter A, Vermeersch S, Delporte A, Demeyere B, Vuylsteke M, Lalla M, Smart T, Detalle L, Bouw R, Streffer J, Degeeter T, Vergotte M, Guisez T, Van Braeckel E, Van Der Straeten C, Lambrecht BN.
Trials · letter; clinical trial protocol · DOI 10.1186/s13063-020-04884-0Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.
Howard JF, Nowak RJ, Wolfe GI, Freimer ML, Vu TH, Hinton JL, Benatar M, Duda PW, MacDougall JE, Farzaneh-Far R, Kaminski HJ, Zilucoplan MG Study Group, Barohn R, Dimachkie M, Pasnoor M, Farmakidis C, Liu T, Colgan S, Benatar MG, Bertorini T, Pillai R, Henegar R, Bromberg M, Gibson S, Janecki T, Freimer M, Elsheikh B, Matisak P, Genge A, Guidon A, David W, Habib AA, Mathew V, Mozaffar T, Hinton JL, Hewitt W, Barnett D, Sullivan P, Ho D, Howard JF, Traub RE, Chopra M, Kaminski HJ, Aly R, Bayat E, Abu-Rub M, Khan S, Lange D, Holzberg S, Khatri B, Lindman E, Olapo T, Sershon LM, Lisak RP, Bernitsas E, Jia K, Malik R, Lewis-Collins TD, Nicolle M, Nowak RJ, Sharma A, Roy B, Nye J, Pulley M, Berger A, Shabbir Y, Sachdev A, Patterson K, Siddiqi Z, Sivak M, Bratton J, Small G, Kohli A, Fetter M, Vu T, Lam L, Harvey B, Wolfe GI, Silvestri N, Patrick K, Zakalik K, Duda PW, MacDougall J, Farzaneh-Far R, Pontius A, Hoarty M.
JAMA Neurol · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1001/jamaneurol.2019.5125